



Company presentation

February 2011

NEUROSEARCH

Forward looking disclaimer



This presentation contains certain “forward-looking Statements”, relating to NeuroSearch activities and business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “should” or other similar expressions, or by discussions of strategy, plans or intentions. Such forward-looking statements reflect the current views of the company with respect to future events and are based on data, assumptions and estimates that the company considers to be reasonable. Many factors could cause the actual results, performance or achievements of NeuroSearch to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with product discovery and development, uncertainties related to the performance and outcome of clinical trials, unforeseen product safety issues, issues relating to manufacturing, market approval or acceptance of NeuroSearch products, competition, intellectual property issues, market conditions and general economic conditions. Should one or more of these risks or uncertainties materialize, or should other risks or uncertainties not foreseen or not identified materialize or should underlying assumptions prove incorrect, the actual results of the company may be materially and adversely affected as compared the forward-looking statements described in this presentation. NeuroSearch does not undertake to meet, or give any guarantee that it will meet, the intentions or goals that may be described in this presentation.

Contents




- NeuroSearch business model
- Speciality Pharma division
- Huntexil® (Huntington's disease); Unique product opportunity
- Proprietary pipeline
- Discovery division - NsDiscovery
- Tesofensine (Obesity); Attractive drug profile in weight management
- Pipeline of drugs aimed for partnering
- Management
- Expected 12 months news flow



NeuroSearch

- Building a speciality pharma company



NeuroSearch - a speciality pharma company




- Focused on specialty and orphan indications in CNS
- Leading programme is Huntexil®
- Concluded Phase II/III studies (HART and MermaiHD)
- Pending FDA/EMA interaction and feedback
 - will we need additional Phase III study?
- Build in-house commercial competencies to take Huntexil® on the market in Europe and North America
- Huntexil® has a large financial potential and is an ideal entry candidate
- Long-term profitability based on the discovery, development and commercialization of CNS speciality drugs



What is Huntington's disease?



- Fatal, neurodegenerative, hereditary disorder (mutant Huntingtin gene);
Causing nerve cell death in several brain areas, leading to circuitry disruptions
- Symptoms onset typically around 30-50 years of age
 - Serious motor disturbances/loss of motor function
 - Cognitive impairment
 - Psychiatric and behavioural changes
- Continuous disease progression over 10-20 years after symptoms onset
- Patients in mid to final disease stages require extensive daily care




Huntington's disease has serious negative implications on quality of life for patients and their families

Huntexil® - A unique product opportunity



- **Huntexil® - A novel and unique therapeutic offering**
 - Shown beneficial effects on patients' core motor symptoms
 - First drug to improve both voluntary and involuntary movements with no apparent worsening of other disease signs and symptoms
 - Favourable tolerability and safety profile (up to 12 months treatment)
 - Belongs to a novel class of pharmaceutical agents with unique properties
- **Attractive commercial case**
 - Orphan Drug Status with both the FDA and the EMA
 - Strong IP (Composition-of-matter patent runs till 2020); All commercial rights retained
 - Highly centralised market: Expected HD sales force of 20-30 specialist reps



Huntexil® - The Phase II/III programme in HD



The MermaiHD study – A European Phase III study

- Randomised, double-blind and placebo controlled study in 437 patients
- Objective: Evaluate efficacy and safety of Huntexil® (45 mg o.d or tw.d) after 26 weeks

The HART study – A North American Phase IIB study

- Randomised, double-blind, and placebo controlled study in 227 patients
- Objective: Evaluate efficacy and safety of Huntexil® (10mg, 22.5mg og 45 mg – all tw.d) after 12 weeks + establish dose-response relationship

Endpoints for both studies

Primary (PE): the modified Motor Score (mMS)

Other: the Total Motor Score (TMS); sub motor domains; the Unified HD Rating Scale (UHDRS)

The MermaiHD safety extension

- 26 week open-label study in 353 patients (who completed the randomised study)
- Objective: Evaluate the safety/tolerability of Huntexil® (45 mg tw.d) for up to 12 months




The MermaiHD study: Efficacy results

In the MermaiHD study, significant effects on total motor function were seen after 26 wk of treatment with Huntexil[®] (45 mg twice daily).

- Although the pre-defined significance level of $p < 0.025$ for the PE (mMS) was not met


The modified Motor Score, mMS (PE)

(mean +/- SEM, p values (ANCOVA (ITT, LOCF); adjustment for baseline score, neuroleptics (yes/no), gender, treatment))



The Total Motor Score, TMS

(mean +/- SEM, p values (ANCOVA (ITT, LOCF); adjustment for baseline score, neuroleptics (yes/no), gender, treatment))



The difference of app. 3 points TMS corresponds to an average absence of clinical deterioration over 6-8 mo


The HART-study: Efficacy results



The HART study results were consistent with the MermaiHD study results: 12 wk treatment with Huntexil® (45mg twice daily) showed significant effect on total motor function – yet, only with a trend for effect on the PE


The modified Motor Score, mMS (PE)

(mean +/- SEM , p values (ANCOVA (ITT, LOCF); adjustment for baseline score, age, treatment)





The Total Motor Score, TMS

(mean +/- SEM , p values (ANCOVA (ITT, LOCF); adjustment for baseline score, age, treatment)



A clear dose-response effect was demonstrated and 12 w data showed app. 1 point change on the mMs and 3 points change on the TMS in favour of Huntexil 45 mg twice daily

Total motor improvement and no symptoms worsening



Mean differences (95% CI) between Huntexil® (45 mg twice daily) and placebo

The Phase II/III programme - Conclusions



- Huntexil[®] has unique and beneficial effect on core motor function in patients with Huntington's disease

- Effect on total motor function demonstrated in two clinical studies
 - Statistically significant effect seen on the Total Motor Score, TMS with improvements of both voluntary and involuntary movements
 - Clear effect trend seen on the modified Motor Score, mMS
 - Significant effect on important sub motor domains relating to functionality :
Balance & gait - Hand movements
 - Dose-response relationship established (the HART study)

- Favourable safety and tolerability profile seen for Huntexil[®] including no apparent worsening of other HD signs or symptoms

Other speciality drug candidates

NEUROSEARCH

Pipeline of CNS speciality drugs



Product	Indication	Mechanism of action	Preclinical	Phase I	Phase II	Phase III	Market reg.
Huntexil®	Huntington's disease	Dopidine					
Seridopidine	Tourette's & PD	Dopidine					
Ordopidine	PD dyskinesias (LID)	Dopidine					
NSD-726	Huntington's disease	Ion channel modulator					
NSD-801	Ataxia	Ion channel modulator					

Dopidines: A novel class of CNS active agents



Dopidines

- A novel class of CNS active pharmacological agents, established by NeuroSearch
- Unique stabilising effects on psychomotor function
- have the potential to treat several neurological and psychiatric disorders characterized by **altered dopamine transmission**, including Huntington's disease

The dopaminergic stabilising properties of dopidines

- Act primarily on dopamine D₂-receptors with unique pharmacodynamic actions
- Able to regulate both hyper- (too high) and hypo- (too low) psychomotor functioning
- Display state dependent behavioural effects with only subtle effect on normal behaviour

Dopidines in the NeuroSearch pipeline

- Huntexil® (pridopidine) for Huntington's disease: the first dopidine that have been evaluated for clinical effect
- Seridopidine and ordopidine are being evaluated in movement disorders within CNS diseases

NsDiscovery division

NEUROSEARCH

NsDiscovery division



- Founded on 20 years of success
- World leader within ion channel discovery
- Impressive track record of alliances
 - GSK, Abbott, Lilly, Johnson & Johnson
- We currently have two ongoing partnerships
 - Lilly
 - Johnson & Johnson
- We aim to build cash neutral/positive partnerships – with milestones and royalties
- NsDiscovery has an impressive partner pipeline, including tesofensine



Building value – Future business prospects



➤ **Corporate assets**

- **Development portfolio:** Advanced CNS drug candidates (incl. Tesofensine)
- **Scientific excellence:** Cutting-edge expertise & state-of-the-art technology platform in ion channel and CNS drug research
- **Innovation:** Several ion channel discovery projects available for partnering

➤ **Strategic objectives**

- To secure sustainable financing of operations *and* future revenue through:
- Timely delivery of drug candidates in Lilly and Johnson & Johnson alliances
- Aiming at new discovery & development partnerships (direct financing + milestones & royalties)

Portfolio of drug candidates aimed for partnering



Product	Indication	Partner	Phase I	Phase II	Phase III	Market reg.
Tesofensine	Obesity					
ABT-894	ADHD	Abbott				
ABT-560	CNS diseases	Abbott				
NSD-788	Anxiety/depression					
NSD-721	Social anxiety disorder					

Phase III ready anti-obesity drug - Tesofensine



Problem statement

- Obesity is an epidemic spiral out of control with an overweight and obese adult population of 50% across OECD countries
- Very few pharmacotherapies available due to regulatory withdrawals or rejection of applications


Tesofensine – a future treatment option?

- It is the most promising weight loss profile for a single agent ever seen but increase in blood pressure and heart rate is a challenge
- The regulatory hurdle is being managed and a revised phase III program is currently under discussion with the EU and the US health authorities
- A partner is to sponsor the remaining development costs and commercialization
- Tesofensine is a valuable asset to NeuroSearch and all efforts will be done to attract/select a partner during 2011

Corporate Management

NEUROSEARCH

Management



Expected news flow

NEUROSEARCH

Expected 12 months news flow



➤ Huntexil®

- Regulatory interactions in US and EU and decision on registration strategy, H1
- Publications of the results from the MermaiHD and the HART studies
- Conclusions from Cost-of-Illness study
- Potential initiation of Early Access programme in Europe

➤ Tesofensine

- Partnering activities

➤ Seridopidine and Ordopidine

- Programme progress late 2011

➤ Other news

- Financial guidance, march 2011
- Potential new partnerships in NsDiscovery, end 2011
- Advances and potential exit for the associated companies
- Other pipeline news





For more information, please visit www.neurosearch.com or write to investor@neurosearch.dk

NEUROSEARCH